Clinical trials: Stage III Cervical Cancer
Head and Neck Cancer, Precancerous Condition
Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or…
- Trial name
- NCT01302834
- Testing
- cetuximab, cisplatin, IMRT
- Where
- 185 sites in United States, Canada
- Volunteers
- 987 people
- Sponsor
- Radiation Therapy Oncology Group
Cervical Cancer, Endometrial Cancer
Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer
RATIONALE: Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause…
- Conditions
- Cervical Cancer, Endometrial Cancer, Gastrointestinal Complications, Perioperative/Postoperative Complications
- Trial name
- NCT01672892
- Testing
- Standard radiation therapy, intensity-modulated radiation therapy
- Where
- 137 sites in United States, Canada and 2 more
- Volunteers
- 289 people
- Sponsor
- Radiation Therapy Oncology Group
Head and Neck Neoplasms, Carcinoma, Squamous Cell
LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy
This randomised, open-label, phase III study will be performed in patients with R/M head and neck squamous cell carcinoma (HNSCC) who have progressed after platinum-based therapy.
- Trial name
- NCT01345682
- Testing
- Afatinib, Methotrexate
- Where
- 101 sites in United States, Argentina and 17 more
- Volunteers
- 483 people
- Sponsor
- Boehringer Ingelheim
Head and Neck Cancer
Adjuvant Cetuximab and Chemoradiotherapy Using Either Cisplatin or Docetaxel in Treating Patients With Resected Stage III or Stage IV Squamous Cell Carcinoma or Lymphoepithelioma of the Head and Neck
RATIONALE: Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00084318
- Testing
- cetuximab, cisplatin, docetaxel
- Where
- 160 sites in United States
- Volunteers
- 238 people
- Sponsor
- Radiation Therapy Oncology Group
Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8
Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers
This phase I trial investigates the side effects and best dose of adavosertib and how well it works when given in combination with radiation therapy in treating patients with esophageal or gastroesophageal junction cancer for…
- Conditions
- Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8
- Trial name
- NCT04460937
- Testing
- Adavosertib, Radiation Therapy
- Where
- 7 sites in United States
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Cervical Adenocarcinoma, Advanced Cervical Adenosquamous Carcinoma
Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer
This phase I trial studies the side effects and best dose of triapine when given with radiation therapy and cisplatin in treating patients with stage IB2-IVA cervical or vaginal cancer.
- Conditions
- Advanced Cervical Adenocarcinoma, Advanced Cervical Adenosquamous Carcinoma, Advanced Cervical Squamous Cell Carcinoma, Advanced Vaginal Adenocarcinoma
- Trial name
- NCT02595879
- Testing
- Biospecimen Collection, Brachytherapy, Cisplatin
- Where
- 17 sites in United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx
Cisplatin and Radiation Therapy With or Without Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Head and Neck Cancer
This randomized phase II trial is studying cisplatin and radiation therapy together with or without erlotinib hydrochloride to compare how well they work in treating patients with stage III or stage IV head and neck cancer.
- Conditions
- Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx
- Trial name
- NCT00410826
- Testing
- erlotinib hydrochloride, cisplatin, 3-dimensional conformal radiation therapy
- Where
- 9 sites in United States
- Volunteers
- 204 people
- Sponsor
- University of Washington
Cutaneous Squamous Cell Carcinoma
Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma
The primary objective of the study is to evaluate the efficacy of neoadjuvant cemiplimab as measured by Pathologic complete response (pCR) rate per independent central pathology review.
- Trial name
- NCT04154943
- Testing
- Cemiplimab
- Where
- 22 sites in United States, Australia and 1 more
- Volunteers
- 79 people
- Sponsor
- Regeneron Pharmaceuticals
Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Soft Palate
Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity
The purpose of this study was to determine whether LI administered in combination with cyclophosphamide, indomethacin and zinc in a multivitamin (CIZ) combination prior to standard of care therapy (surgery followed by…
- Trial name
- IT-MATTERS (NCT01265849)
- Testing
- LI, Cyclophosphamide, Indomethacin
- Where
- 102 sites in United States, Austria and 21 more
- Volunteers
- 928 people
- Sponsor
- CEL-SCI Corporation
Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer
Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer
Drugs used in chemotherapy, such as docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth.
- Trial name
- NCT00088907
- Testing
- docetaxel, gefitinib
- Where
- United States
- Volunteers
- 270 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
This randomized phase III trial studies how well radiation therapy, paclitaxel, and carboplatin with or without trastuzumab work in treating patients with esophageal cancer.
- Conditions
- Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Stage IB Esophageal Cancer AJCC v7, Stage IIA Esophageal Cancer AJCC v7
- Trial name
- NCT01196390
- Testing
- Carboplatin, Laboratory Biomarker Analysis, Paclitaxel
- Where
- 634 sites in United States
- Volunteers
- 203 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer
Pemetrexed and Oxaliplatin in Treating Patients With Locally Advanced Head and Neck Cancer
RATIONALE: Pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00503997
- Testing
- oxaliplatin, pemetrexed disodium
- Where
- 7 sites in United States
- Volunteers
- 42 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Recurrent Thyroid Gland Carcinoma, Stage III Thyroid Gland Follicular Carcinoma
Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
This phase II trial is studying how well aflibercept works in treating patients with recurrent and/or metastatic thyroid cancer that has not responded to radioactive iodine therapy.
- Conditions
- Recurrent Thyroid Gland Carcinoma, Stage III Thyroid Gland Follicular Carcinoma, Stage III Thyroid Gland Papillary Carcinoma, Stage IV Thyroid Gland Follicular Carcinoma
- Trial name
- NCT00729157
- Testing
- Fludeoxyglucose F-18, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Cancer, Gastric Cancer
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00985192
- Testing
- everolimus, laboratory biomarker analysis
- Where
- 18 sites in United States
- Volunteers
- 49 people
- Sponsor
- Translational Oncology Research International
Cervical Cancer
Cetuximab and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00101192
- Testing
- cetuximab, cisplatin
- Where
- 18 sites in United States
- Volunteers
- 76 people
- Sponsor
- Gynecologic Oncology Group
Papillomavirus Infections, Uterine Cervical Neoplasms
Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)
This study will evaluate the safety and immunogenicity of V503 (GARDASIL™9, 9vHPV vaccine) administered to 9- to 26-year-old females and males in Vietnam.
- Conditions
- Papillomavirus Infections, Uterine Cervical Neoplasms, Vulvar Neoplasms, Vaginal Neoplasms
- Trial name
- NCT03546842
- Testing
- 9vHPV vaccine
- Where
- Vietnam
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cervical Cancer
Fluorine F 18 EF5 PET/CT Imaging in Patients With Locally Advanced or Recurrent/Metastatic Cervical Cancer
RATIONALE: Diagnostic procedures, such as fluorine F 18 EF5 PET/CT imaging, may help find oxygen in tumor cells. It may also help doctors predict a patient's response to treatment and help plan the best treatment.
- Trial name
- NCT00978874
- Testing
- fludeoxyglucose F 18, fluorine F 18 EF5
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Head and Neck Cancer, Oral Complications of Radiation Therapy
Radiation Therapy With or Without Chemotherapy in Reducing Mouth Dryness in Patients With Nasopharyngeal Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation therapy in different ways may cause less damage to normal tissue, prevent or lessen mouth dryness, and may help patients live more…
- Conditions
- Head and Neck Cancer, Oral Complications of Radiation Therapy, Radiation Toxicity
- Trial name
- NCT00057785
- Testing
- cisplatin, fluorouracil, Intensity modulated radiation therapy
- Where
- 17 sites in United States
- Volunteers
- 68 people
- Sponsor
- Radiation Therapy Oncology Group
Esophageal Cancer
Esophagectomy in Treating Patients With High-Grade Dysplasia of the Esophagus or Stage I, Stage II, or Stage III Esophageal Cancer
RATIONALE: Laparoscopic-assisted surgery and video-assisted thoracoscopy are less invasive types of surgery for esophageal cancer that may have fewer side effects and improve recovery.
- Trial name
- NCT00063986
- Testing
- Minimally invasive esophagectomy (MIE)
- Where
- 41 sites in United States
- Volunteers
- 110 people
- Sponsor
- Eastern Cooperative Oncology Group
Cervical Cancers, Vulvar Cancers
A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)
This study will evaluate whether V503 (9vHPV vaccine), is well tolerated in girls and women between 12 and 26 years old who have previously been vaccinated with GARDASIL™.
- Conditions
- Cervical Cancers, Vulvar Cancers, Vaginal Cancers, Genital Warts
- Trial name
- NCT01047345
- Testing
- V503
- Volunteers
- 924 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC